ArticleNPJ precision oncology2026
The phosphoproteome of ovarian carcinoma delineates signaling signatures and potentially druggable targets across histotype stages.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Ovarian malignancy is the most lethal gynecologic tumor, with an 80% relapse rate and 47% five-year survival. Epithelial ovarian cancer (EOC), the most common form, comprises five major histotypes with distinct clinicopathological characteristics, yet treatment still relies largely on cytoreductive surgery and platinum-based chemotherapy. Phosphoproteomics enables the mapping of protein phosphorylation, a key hallmark of cellular signaling. This study aimed to define phosphoproteomic-based ovarian cancer subgroups and assess their relationships with pathway activation patterns, patient prognosis, and therapeutic relevance. We analyzed the phosphoproteome of four major EOC histotypes from 180 patients. Dysregulated phosphosites critical for carcinogenesis were identified, including NUCKS1:S181, WWTR1:S89, and SRRM2:T1880. Kinase activity revealed histotype-specific CDK1/2 signatures linked to EOC-related signaling pathways. Prognostic phosphosites displayed stage- and histotype-dependent patterns. Collectively, these findings elucidate signaling cascades driving disease progression and identify potential therapeutic targets in early and advanced EOC, supporting future efforts toward the development of histotype-specific treatment strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.